U.S. markets open in 5 hours
  • S&P Futures

    4,260.50
    -26.00 (-0.61%)
     
  • Dow Futures

    33,841.00
    -140.00 (-0.41%)
     
  • Nasdaq Futures

    13,416.50
    -106.75 (-0.79%)
     
  • Russell 2000 Futures

    1,987.10
    -14.60 (-0.73%)
     
  • Crude Oil

    89.46
    -1.04 (-1.15%)
     
  • Gold

    1,765.90
    -5.30 (-0.30%)
     
  • Silver

    19.15
    -0.32 (-1.64%)
     
  • EUR/USD

    1.0089
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    2.8800
    0.0000 (0.00%)
     
  • Vix

    20.23
    +0.33 (+1.66%)
     
  • GBP/USD

    1.1894
    -0.0039 (-0.33%)
     
  • USD/JPY

    136.5660
    +0.7040 (+0.52%)
     
  • BTC-USD

    21,787.27
    -1,612.49 (-6.89%)
     
  • CMC Crypto 200

    517.35
    -40.38 (-7.24%)
     
  • FTSE 100

    7,537.82
    -4.03 (-0.05%)
     
  • Nikkei 225

    28,930.33
    -11.81 (-0.04%)
     

HC Wainwright Downgrades Angion Biomedica

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Last month, Angion Biomedica Corp (NASDAQ: ANGNdiscontinued the JUNIPER Phase 2 dose-finding trial of ANG-3070 in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.

  • HC Wainwright downgraded the stock to Neutral from Buy without a price target.

  • The analysts say that Angion continues to pursue a Phase 1b study of ANG-3070 in patients with idiopathic pulmonary fibrosis (IPF). Topline data remain scheduled to release later this year.

  • "While we do not expect to get a sense of efficacy from this trial, it may pave the way for ANG-3070 to move into proof-of-concept IPF clinical assessment next year. We also expect safety and tolerability data in IPF patients to be generated from the Phase 1b trial," notes HC Wainwright.

  • "While we remain cautiously optimistic regarding ANG-3070's potential in IPF, we recognize that this will take time to realize. In the wake of the JUNIPER discontinuation," the analysts added.

  • Price Action: ANGN shares are down 2.36% at $1.04 during the market session on the last check Monday.

Latest Ratings for ANGN

Date

Firm

Action

From

To

Dec 2021

Oppenheimer

Maintains

Outperform

Nov 2021

HC Wainwright & Co.

Maintains

Buy

Oct 2021

Stifel

Maintains

Buy

View More Analyst Ratings for ANGN

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.